Q2 2026 Earnings Confirm a Holding Pattern, Gardasil Restart Remains Elusive

What happened

Merck's Q2 2026 results showed incremental progress from new launches like Winrevair and Capvaxive, yet the core narrative remains dominated by the Gardasil-China shipment pause and the $2.5 billion FY2026 headwind. Management provided no timeline for a Gardasil restart, reinforcing the view that China inventory clearance is still unresolved. The Terns acquisition closed as expected, adding pipeline depth but also near-term integration costs. On the positive side, the April FDA approval of subcutaneous Keytruda strengthens franchise defense ahead of biosimilar competition. Overall, the quarter leaves the investment thesis intact, with no new catalyst to break the stock out of its tight range.

Implication

Investors should track quarterly headwind updates and China shipment resumption; if the $2.5B erosion grows or the pause extends into 2027, consider trimming positions. Conversely, a restart announcement and stable guidance could validate an attractive entry near $105, supporting a re-rating toward the base case of $125.

Thesis delta

The thesis remains unchanged: Merck's near-term fate hinges on proving that non-Keytruda pillars can offset the $2.5B headwind and that Gardasil-China normalizes. Q2 results delivered expected Keytruda line-extension approval but no clarity on China, keeping the stock in a wait-and-see pattern. We maintain our WAIT rating and price targets, with conviction tied to the next 1-2 quarterly updates on the China resumption and headwind trajectory.